Released Aug 11, 2025, after the close
10-Q filed Aug 15, 2025, 46 days after period end · 0000950170-25-109388
Q2 2025 · 10-Q
Revenue$21.76M$21.76M −3.2% vs Q2 2024+7.6% vs Q1 2025
Net Income-$33.46M-$33.46M N/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.09-$0.09 N/M vs Q2 2024N/M vs Q1 2025
Gross Profit$10,628,000+2.4%
Operating Income-$25,697,000N/M
Operating Cash Flowderived-$20,668,000N/M
Free Cash Flowderived-$22,555,000N/M
Margins · derived
Gross margin48.8%+2.7 pt vs Q2 2024
Operating margin-118.1%+16.5 pt vs Q2 2024
Net margin-153.7%+49.5 pt vs Q2 2024
What the release said
The release
Same quarter
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $21.76M | $22.49M | $27.67M | $18.78M |
| Net Income | -$33.46M | -$45.72M | -$17.04M | -$63.54M |
| EPS Diluted | -$0.09 | -$0.12 | -$0.22 | -$0.82 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR